Skip to main content

Protagonist Therapeutics, Inc (PTGX)

Sector
Healthcare
Industry
Biotechnology
Last price
$124.67
As of

Kresmion compiles this page from PTGX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Protagonist Therapeutics, Inc (PTGX): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-06.

As of . Source: SEC EDGAR filings for PTGX. Method and limitations.

COMPANY DOSSIER

See the full PTGX dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for PTGX on one page. Preview it with sample data, then open it live with a free account.

Preview the PTGX dossier

Active events for PTGX

FREE, NO ACCOUNT

Every event on PTGX, as it fires

You are seeing 5 of 10 events recorded on PTGX since 2026-05-27.

The five above landed across 3 days. The other 5 were recorded on 3 other days. 5 of the 10 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

PTGX positions held by the managers we follow (2026Q3)

What the managers we follow bought and sold in Q2 2026

Manager / securityMarket value% of reported value
RENAISSANCE TECHNOLOGIES LLC FundCUSIP 74366E102 · 2026Q3$10.8M0.01%

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, PTGX

More data on PTGX

PTGX against its peers

PTGX's operating margin of -343.6% ranks in the 32nd percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-09-30.

MetricPTGXPeer medianPercentilen
Revenue FY46.0M USD190M USD3415
Operating margin-343.6%-101.2%3213
Net margin-282.8%-103.6%3913
Return on equity-21.2%-34.1%7021
1 year48.3%44.8%6020

Peers (24): CYTK, RYTM, ALKS, PRAX, KRYS, ABVX, CRNX.D, CAI, SYRE, SMMT, TGTX, ORKA, PCVX, KOD, CGON, NUVL.D, ARWR, MDGL, APGE.D, IBRX, LGND, IMVT, CNTA.D, BLTE. Left out: BCHMY (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-09-30. Every figure is one full fiscal year read from one annual filing (PTGX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

Cite this data

Kresmion counts the managers it follows that reported a non-option position in PTGX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on PTGX in the last 180 days.

Upstream: SEC EDGAR filings for PTGX

Kresmion, "Protagonist Therapeutics, Inc (PTGX) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/PTGX. Upstream data: SEC EDGAR filings for PTGX.

Link to this data (HTML):

<a href="https://kresmion.com/research/PTGX">Protagonist Therapeutics, Inc (PTGX) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow PTGX on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to PTGX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the PTGX dossier
Share

The PTGX intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.